Search
-
Virtual Reality: Hype or the Future?
Virtual Reality (VR) technology has been around for at least a decade and you could say it’s clearly gone from sci-fi to sci-fact. However, it’s still seen as a new technology and has not hit mass adoption; so what has gone wrong?
-
Four Ways Agile Research Will Evolve to Drive Innovation
In today’s fast-moving, shape-shifting world, it seems virtually every business, every marketer, and every researcher wants to be agile. But, what exactly does agility mean?
-
Ipsos Update - July 2018
Welcome to Ipsos Update – our monthly selection of research and thinking from Ipsos teams around the world. July’s edition features new papers on ethnography, audience measurement and food waste, as well as new global reports on the inclusiveness of nationalities and artificial intelligence.
-
Ipsos Update – November 2017
Welcome to the November edition of Ipsos Update – our monthly selection of research and thinking from Ipsos teams around the world.
-
Smartificial Intelligence
Artificial Intelligence is often mooted as the ‘future’ for our industry. Many lead us to believe that we are headed for an AI utopia; that ‘optimised’ ad experiences fuelled by big data insights gleaned solely by machines, tailored to individuals, and served to them programatically with impeccable timing in the right time and right context, is almost within reach. However, when we take a step back to consider this, how close are we really; and is it even what we want at all?
-
Global Business Influencers 2017 Survey Launch
Global Business Influencers are the driving force behind business and investment decisions globally, leading their companies into a future where disruption is becoming the norm and technology is at the top of the agenda for many.
-
Ipsos Update - October 2017
Welcome to the October edition of Ipsos Update – our monthly selection of research and thinking from Ipsos teams around the world.
-
Conquering Complexity: The Coming Revolution in Oncology Biomarker Testing
Despite the advent of targeted therapies and the associated rise in the use of companion and complementary diagnostics, we are only just emerging from the initial exploratory stages of oncology biomarker testing. As will be argued in this paper, we are on the cusp of a much more radical revolution, and the molecular diagnostics landscape is set to change dramatically in the coming decades. It is crucial that any company entering this space prepare for this imminent upheaval and plan their launch strategy accordingly.